AAMU
RVNC

Amundi Asset Management US’s Revance Therapeutics, Inc. RVNC Stock Holding History

Amundi Asset Management US’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,400
Closed -$181K – 1580
2020
Q4 		$181K Hold
6,400
– – ﹤0.01% 1413
2020
Q3 		$161K Buy
+6,400
New +$168K ﹤0.01% 1403

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Amundi Asset Management US's RVNC Position: Q1 2021 in Review

Amundi Asset Management US sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2021, closing a stake of 6,400 shares — an estimated $181K sold.

Amundi Asset Management US first reported a position in RVNC in Q3 2020 and held it in 2 quarters. The position peaked at $181K in Q4 2020. 149 funds tracked by Wall St. Rank hold RVNC as of Q1 2021.

  • Amundi Asset Management US reported no remaining Revance Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Amundi Asset Management US sold 6,400 Revance Therapeutics, Inc. shares in Q1 2021, an estimated $181K.
  • Amundi Asset Management US first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 2 quarters.
  • Amundi Asset Management US's Revance Therapeutics, Inc. position peaked at $181K in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.